SGAM
CLDX icon

Smith Group Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Smith Group Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,399
Closed -$901K – 418
2014
Q1 		$901K Buy
+3,399
New +$1.3M 0.03% 185

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Smith Group Asset Management's CLDX Position: Q2 2014 in Review

Smith Group Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 3,399 shares — an estimated $901K sold.

Smith Group Asset Management first reported a position in CLDX in Q1 2014 and held it in 1 quarter. The position peaked at $901K in Q1 2014. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • Smith Group Asset Management reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Smith Group Asset Management sold 3,399 Celldex Therapeutics shares in Q2 2014, an estimated $901K.
  • Smith Group Asset Management first reported a position in Celldex Therapeutics in Q1 2014 and held it in 1 quarter.
  • Smith Group Asset Management's Celldex Therapeutics position peaked at $901K in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on Smith Group Asset Management's 13F filing for Q2 2014, filed 23 Jul 2014.